Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA; email:
Annu Rev Virol. 2020 Sep 29;7(1):447-473. doi: 10.1146/annurev-virology-021920-113833.
Hendra virus (HeV) and Nipah virus (NiV) are bat-borne zoonotic para-myxoviruses identified in the mid- to late 1990s in outbreaks of severe disease in livestock and people in Australia and Malaysia, respectively. HeV repeatedly re-emerges in Australia while NiV continues to cause outbreaks in South Asia (Bangladesh and India), and these viruses have remained transboundary threats. In people and several mammalian species, HeV and NiV infections present as a severe systemic and often fatal neurologic and/or respiratory disease. NiV stands out as a potential pandemic threat because of its associated high case-fatality rates and capacity for human-to-human transmission. The development of effective vaccines, suitable for people and livestock, against HeV and NiV has been a research focus. Here, we review the progress made in NiV and HeV vaccine development, with an emphasis on those approaches that have been tested in established animal challenge models of NiV and HeV infection and disease.
亨德拉病毒(HeV)和尼帕病毒(NiV)是分别在 20 世纪 90 年代中后期在澳大利亚和马来西亚暴发的严重牲畜和人类疾病中发现的蝙蝠传播的人畜共患病副黏病毒。HeV 在澳大利亚反复出现,而 NiV 继续在南亚(孟加拉国和印度)引发暴发,这些病毒仍然是跨境威胁。在人和几种哺乳动物中,HeV 和 NiV 感染表现为严重的全身性疾病,且常导致死亡,主要为神经系统和/或呼吸系统疾病。由于其相关的高病死率和人际传播能力,NiV 是一种潜在的大流行威胁。针对 HeV 和 NiV 开发有效疫苗,适用于人和牲畜,一直是研究重点。在此,我们综述了 NiV 和 HeV 疫苗开发方面的进展,重点介绍了那些已在 NiV 和 HeV 感染和疾病的既定动物挑战模型中进行测试的方法。